安徽华恒生物科技股份有限公司 关于董事会换届选举的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688639 证券简称：华恒生物 公告编号：2025-048 安徽华恒生物科技股份有限公司（以下简称"公司"）第四届董事会任期即 将届满，根据《中华人民共和国公司法》（以下简称《公司法》）《上海证券交易 所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号 ——规范运作》等法律法规、规范性文件以及《公司章程》等规定，公司开展董 事会换届选举工作。现将相关情况公告如下： 一、董事会换届选举情况 公司于 2025 年 10 月 27 日召开第四届董事会第二十四次会议，审议通过《关 于选举公司第五届董事会非独立董事的议案》及《关于选举公司第五届董事会独 立董事的议案》，同意提名郭恒华女士、郭恒平先生、张学礼先生、张冬竹先生、 樊义先生为公司第五届董事会非独立董事候选人；同时同意提名陈继忠先生、吴 林先生、WANG FUCAI（王富才）先生为公司第五届董事会独立董事候选人。 独立董事候选人陈继忠先 ...

独立董事提名人声明与承诺 二、被提名人任职资格符合下列法律、行政法规和部门规 章的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （二）中国证监会《上市公司独立董事管理办法》、上海证 券交易所自律监管规则以及公司章程有关独立董事任职资格和 条件的相关规定； （三）其他法律法规、部门规章、规范性文件和上海证券 交易所规定的情形。 三、被提名人具备独立性，不属于下列情形： （一）在上市公司或者其附属企业任职的人员及其配偶、 父母、子女、主要社会关系（主要社会关系是指兄弟姐妹、兄 弟姐妹的配偶、配偶的父母、配偶的兄弟姐妹、子女的配偶、 子女配偶的父母等）； （二）直接或者间接持有上市公司已发行股份 1%以上或 者是上市公司前十名股东中的自然人股东及其配偶、父母、子 女； （三）在直接或者间接持有上市公司已发行股份 5%以上 的股东或者在上市公司前五名股东任职的人员及其配偶、父母、 子女； 提名人安徽华恒生物科技股份有限公司董事会，现提名陈 继忠先生为安徽华恒生物科技股份有限公司第五届董事会独立 董事候选人，并已充分了解被提名人职业、学历、职称、详细 的工作经历、全部兼职、有无重大失信等不良记录等情况 ...

独立董事提名人声明与承诺 提名人安徽华恒生物科技股份有限公司董事会，现提名吴 林先生为安徽华恒生物科技股份有限公司第五届董事会独立董 事候选人，并已充分了解被提名人职业、学历、职称、详细的 工作经历、全部兼职、有无重大失信等不良记录等情况。被提 名人已同意出任安徽华恒生物科技股份有限公司第五届董事会 独立董事候选人（参见该独立董事候选人声明）。提名人认为， 被提名人具备独立董事任职资格，与安徽华恒生物科技股份有 限公司之间不存在任何影响其独立性的关系，具体声明并承诺 如下： 一、被提名人具备上市公司运作的基本知识，熟悉相关法 律、行政法规、规章及其他规范性文件，具有 5 年以上法律、 经济、会计、财务、管理或者其他履行独立董事职责所必需的 工作经验。 二、被提名人任职资格符合下列法律、行政法规和部门规 章的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （二）中国证监会《上市公司独立董事管理办法》、上海证 券交易所自律监管规则以及公司章程有关独立董事任职资格和 条件的相关规定； （三）其他法律法规、部门规章、规范性文件和上海证券 交易所规定的情形。 （六）为上市公司及其控股股东、实际控制人或者 ...

独立董事候选人声明与承诺 本人 WANG FUCAI（王富才），已充分了解并同意由提名 人安徽华恒生物科技股份有限公司董事会提名为安徽华恒生物 科技股份有限公司第五届董事会独立董事候选人。本人公开声 明，本人具备独立董事任职资格，保证不存在任何影响本人担 任安徽华恒生物科技股份有限公司独立董事独立性的关系，具 体声明并承诺如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、 行政法规、部门规章及其他规范性文件，具有 5 年以上法律、 经济、会计、财务、管理或者其他履行独立董事职责所必需的 工作经验。 二、本人任职资格符合下列法律、行政法规和部门规章以 及公司规章的要求： （三）其他法律法规、部门规章、规范性文件和上海证券 交易所规定的情形。 三、本人具备独立性，不属于下列情形： （一）在上市公司或者其附属企业任职的人员及其配偶、 父母、子女、主要社会关系（主要社会关系是指兄弟姐妹、兄 弟姐妹的配偶、配偶的父母、配偶的兄弟姐妹、子女的配偶、 子女配偶的父母等）； （二）直接或者间接持有上市公司已发行股份 1%以上或 者是上市公司前十名股东中的自然人股东及其配偶、父母、子 女； （三）在直接或者间接持有上市 ...

证券代码：688639 证券简称：华恒生物 公告编号：2025-049 安徽华恒生物科技股份有限公司 关于召开2025年第三次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2025年第三次临时股东会 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 （四） 现场会议召开的日期、时间和地点 网络投票起止时间：自2025 年 11 月 12 日 至2025 年 11 月 12 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联 股东会召开日期：2025年11月12日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 网投票平台的投票时间为股东会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 ...

Group 1 - The core viewpoint of the article highlights Huaheng Biological's financial performance in Q3 2025, showing significant revenue growth but a decline in net profit and earnings per share [1] Group 2 - For the first three quarters of 2025, Huaheng Biological reported revenue of approximately 2.194 billion yuan, representing a year-on-year increase of 42.53% [1] - The net profit attributable to shareholders was approximately 168 million yuan, reflecting a year-on-year decrease of 1.34% [1] - The basic earnings per share were 0.67 yuan, which is a year-on-year decrease of 9.36% [1] Group 3 - As of the report date, Huaheng Biological's market capitalization stood at 8.6 billion yuan [2]

安徽华恒生物科技股份有限公司2025 年第三季度报告 证券代码：688639 证券简称：华恒生物 安徽华恒生物科技股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人郭恒华、主管会计工作负责人樊义及会计机构负责人朱修发（会计主管人员）保证季 度报告中财务信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 | | | | | 单位：元 | 币种：人民币 | | --- | --- | --- | --- | --- | --- | | | | | 本报告期比 | | 年初至报告期 | | 项目 | | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | | 减变动幅度 | | 增减变动幅度 | | | | | (%) | | (%) | | ...

Core Viewpoint - The A-share market is experiencing a strong upward trend, with major indices rising over 1%, and the Shanghai Composite Index nearing the 4000-point mark, a level not seen since August 2015 [1][2]. Market Performance - The market is characterized by active hotspots, with over 3300 stocks closing in the green. The trading volume in the Shanghai and Shenzhen markets reached 2.34 trillion, an increase of 365.9 billion from the previous trading day [3]. - Key sectors showing significant gains include small metals, electronic chemicals, components, and semiconductors, with notable performance in concepts like storage chips, AI PCs, and Co-Packaged Optics (CPO) [3][4]. Storage Chip Sector - The storage chip sector continues to thrive, driven by exponential demand from AI servers for storage capacity and bandwidth [5]. - Prices for DRAM have surged, with a nearly 100% year-on-year increase in September, and certain DDR4 models seeing price increases of over 300% since April. Major players like Samsung and SK Hynix are expected to raise prices by 30% in Q4 [6]. High-Tech Industry Development - The Chinese government has set a goal to cultivate high-tech industries over the next decade, with projections indicating that the market size of seven key future industries could exceed 10 trillion yuan by 2030 [7]. - The focus is on emerging pillar industries, with the "Three New" economy expected to account for over 18% of GDP by 2024, particularly in sectors like new energy and aerospace [10]. Investment Directions - **Quantum Technology**: Emphasizes a gradient development approach, with quantum measurement leading in commercialization, followed by quantum communication and quantum computing [12]. - **Biomanufacturing**: Driven by technology substitution and scene expansion, with significant potential to replace 20%-30% of chemical products [13]. - **Hydrogen and Nuclear Fusion Energy**: Positioned as complementary forces in the energy revolution, focusing on industrial and transportation decarbonization [14]. - **Brain-Computer Interfaces**: Targeting medical applications first, with consumer applications expected to follow as technology matures [15]. - **Embodied Intelligence**: Focused on industrial applications initially, with consumer applications anticipated to explode later [16]. - **6G Technology**: Aiming for seamless global coverage and integration of AI, with commercial deployment expected by 2030 [17][19].

Core Insights - The article emphasizes that the development of the biomanufacturing industry in China is not merely a "shortcut" but a strategic choice to disrupt traditional industrial systems through technological innovation [2][3] - Biomanufacturing is recognized as a key driver for China's economic growth and sustainable development, with significant government support and policy initiatives [2][3] Industry Overview - The total scale of China's biomanufacturing industry is approaching 1 trillion yuan, with predictions that it will grow to 1.8 trillion yuan by 2030, capturing nearly 25% of the global market [3] - Biomanufacturing encompasses various sectors, including healthcare, industrial chemicals, food supplements, and bioenergy [3] Technological Advancements - Over the past five years, China has filed over 120,000 biomanufacturing-related patents, accounting for 39.5% of the historical total [3] - The industry faces challenges in overcoming technological, model, and institutional bottlenecks, necessitating advancements in AI and automation to improve efficiency [4][5] Industry Structure and Upgrades - The biomanufacturing process involves multiple stages, including cell selection, fermentation optimization, and quality control, with a diverse range of supporting and technical enterprises [6] - Domestic bioreactor market share has increased from below 30% to over 50%, although key sensors and software still rely on imports [6][7] Future Trends - Biomanufacturing is expected to replace traditional chemical methods in various applications, including biodegradable plastics and pharmaceuticals [8] - The industry is poised for significant advancements in drug synthesis and environmental sustainability, with a focus on reducing carbon emissions and improving waste management [8][9]

Industry Overview - The chemical sector experienced a decline of 5.83% from October 13 to October 17, 2025, ranking 26th among all sectors, underperforming the Shanghai Composite Index by 4.36 percentage points and the ChiNext Index by 0.12 percentage points [2][3] Key Trends and Recommendations - The chemical industry is expected to continue its trend of divergence in 2025, with a focus on synthetic biology, pesticides, chromatography media, sweeteners, vitamins, light hydrocarbon chemicals, COC polymers, and MDI [2] - Synthetic biology is anticipated to reach a pivotal moment, driven by energy structure adjustments, with traditional chemical companies needing to adapt to energy consumption and carbon tax costs [2] - The third-generation refrigerants are entering a high prosperity cycle due to supply constraints and increasing demand from markets like Southeast Asia [3] - Electronic specialty gases are critical for the semiconductor industry, with domestic companies poised to benefit from the increasing demand for high-end production capacity [4] - The trend towards light hydrocarbon chemicals is becoming global, with a shift from heavy naphtha to lighter feedstocks like ethane and propane, which are more cost-effective and environmentally friendly [5] - The industrialization of COC/COP materials is accelerating in China, driven by domestic production capabilities and the need for supply chain security [6] - Potash fertilizer prices are expected to rebound as major suppliers reduce output, leading to a tightening supply-demand balance [7][8] - The MDI market is characterized by oligopoly, with a favorable supply structure anticipated as demand recovers, making it a resilient chemical product [9] Price Tracking - Significant price increases were noted for liquid chlorine (553.33%), sulfur (8.80%), and acrylic acid (3.68%), while notable declines were seen in nitrile rubber (-33.13%) and NYMEX natural gas futures (-7.98%) [10] - A total of 165 chemical enterprises reported production capacity impacts, with 8 new maintenance activities and 4 restarts recorded [11]